AGIO vs VERX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AGIO and VERX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AGIO and VERX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia. The company is pursuing accelerated approval of mitapivat in sickle cell disease and, as of July 2026, the FDA granted Priority Review to that application. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).

Full AGIO guide

Vertex, Inc. (NASDAQ: VERX) is a global provider of indirect tax software, content, and services that help large and mid-size enterprises calculate, collect, and report taxes such as sales and consumer use tax, value added tax (VAT), and payroll-related indirect taxes. Its core O Series platform plugs into the ERP, e-commerce, procurement, and billing systems that big companies already run (SAP, Oracle, Workday, Salesforce and others) and applies a continuously updated database of tax rules across thousands of jurisdictions so that the correct tax is applied on every transaction. Founded in 1978 and public since 2020, Vertex serves roughly 4,900 direct customers, many of them large multinationals, and earns the bulk of its revenue from recurring software subscriptions plus related services, with annual recurring revenue per customer of about $137,867 as of late 2025.

Full VERX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AGIO drivers: Mitapivat franchise expansion; Sickle cell Priority Review.
• VERX drivers: Recurring, mission-critical tax compliance; Cloud migration and higher-value expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. For VERX, vertex shares fell roughly 70% over the year to mid-2026, driven by deteriorating key performance indicators in late 2025, extended sales cycles, and reduced growth and margin expectations, so momentum and sentiment have been sharply negative.

Pick AGIO if you believe its drivers more; VERX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AGIO and VERX guides.

AGIO. Agios trades at a large multiple of its small product revenue, reflecting a valuation driven by pipeline potential rather than current earnings. The company is unprofitable, with R&D (~$81M) and SG&A (~$48M) in Q1 2026 far exceeding revenue. The roughly $1 billion cash balance represents a large share of the market capitalization, which cushions financing risk but also signals that the market is paying primarily for future indications like sickle cell disease.

VERX. As of July 2026, Vertex traded at a market cap of about $2.0 billion after losing roughly 70% of its value over the prior year, even though revenue kept growing and adjusted EBITDA was rising. The stock now trades on a much lower revenue multiple than it did at its peak, reflecting reset growth and margin expectations. Whether that repricing is an opportunity or a warning depends on whether growth stabilizes and the 2026 cost plan delivers the promised savings.

Headline figures (approximate, JUNE 2026): AGIO shows revenue (ttm) ~$66M, fy2025 revenue ~$54M, q1 2026 revenue ~$20.7M (up ~138% YoY), q1 2026 gaap eps ~-$1.69; VERX shows market cap ~$2.0 billion, revenue (ttm) ~$775 million, fy2025 revenue ~$752 million, fy2026 revenue guidance ~$823 to $831 million.

AGIO and VERX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AGIO and VERX exposure against your real portfolio. It is not an investment adviser.